Application of TDI Combined with Serum miR-34a in the Diagnosis of Children CHD Complicated with PAH

doi:10.7517/issn.1674-0475.220407

Abstract

Abstract: This study explored the diagnostic value of Tissue Doppler Imaging (TDI) combined with serum microRNA-34a (miR-34a) in the diagnosis of children congenital heart disease (CHD) complicated with pulmonary arterial hypertension (PAH). According to the occurrence of PAH, all 112 CHD children were divided into CHD group and CHD+PAH group and all of them underwent TDI examination. The TDI-Tei and TDI-Z of the two groups were measured respectively, and the serum miR-34a level of the children was detected by qRT-PCR test. The results showed that the TDI-Tei of the CHD group was significantly lower than that of the CHD+PAH group(P<0.001), the TDI-Z of the CHD group was significantly higher than that of the CHD+PAH group(P<0.001), the relative expression of serum miR-34a in CHD group was significantly lower than that in CHD+PAH group(P<0.001). Correlation analysis showed that TDI-Tei was negatively correlated with TDI-Z (r=-0.325, P<0.01), TDI-Tei was positively correlated with serum miR-34a (r=0.260, P<0.01), TDI-Z was negatively correlated with serum miR-34a (r=-0.386, P<0.01). The AUC and the sensitivity of TDI-Tei, TDI-Z and serum miR-34a combined diagnosis of CHD complicated with PAH were higher than those of single diagnosis. In conclusion, TDI combined with serum miR-34a has higher value in the diagnosis of CHD complicated with PAH, and was worthy of clinical promotion.

Key words: congenital heart disease, pulmonary hypertension, tissue Doppler imaging, microRNA-34a, TDI-Tei, TDI-Z

XU Shanshan, CAO Xianying, ZHOU Bin. Application of TDI Combined with Serum miR-34a in the Diagnosis of Children CHD Complicated with PAH[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(5): 1039-1044.

References

[1] Han S, Wei C Y, Hou Z L, et al. Prevalence of congenital heart disease amongst schoolchildren in Southwest China[J]. Indian Pediatrics, 2020, 57(2):138-141.
[2] Wu X L, Li R, Fu F, et al. Chromosome microarray analysis in the investigation of children with congenital heart disease[J]. BMC Pediatrics, 2017, 17(1):117.
[3] Wilkinson K L, Brunskill S J, Doree C, et al. Red cell transfusion management for patients undergoing cardiac surgery for congenital heart disease[J]. The Cochrane Database of Systematic Reviews, 2014(2):Cd009752.
[4] Hamdan A, Shapira Y, Bengal T, et al. Tissue Doppler imaging in patients with advanced heart failure:Relation to functional class and prognosis[J]. The Journal of Heart and Lung Transplantation:the Official Publication of the International Society for Heart Transplantation, 2006, 25(2):214-218.
[5] Lunze F I, Singh T P, Gauvreau K, et al. Comparison of tissue Doppler imaging and conventional echocardiography to discriminate rejection from non-rejection after pediatric heart transplantation[J]. Pediatric Transplantation, 2020, 24(5):e13738.
[6] Tei C, Ling L H, Hodge D O, et al. New index of combined systolic and diastolic myocardial performance:A simple and reproducible measure of cardiac function-A study in normals and dilated cardiomyopathy[J]. Journal of Cardiology, 1995, 26(6):357-366.
[7] Zhou Q, Henein M, Coats A, et al. Different effects of abnormal activation and myocardial disease on left ventricular ejection and filling times[J]. Heart:British Cardiac Society, 2000, 84(3):272-276.
[8] 陈图敏, 李俊辉. TDI-Z指数联合TDI-Tei指数评价左向右分流型先天性心脏病合并肺动脉高压患儿右心功能[J]. 中国医学创新, 2014, 11(20):1-4.
[9] Hoelscher S C, Doppler S A, Dreßen M, et al. microRNAs:Pleiotropic players in congenital heart disease and regenera-tion[J]. Journal of Thoracic Disease, 2017, 9(Suppl 1):S64-s81.
[10] Nagy O, Baráth S, Ujfalusi A. The role of microRNAs incongenital heart disease[J]. EJIFCC, 2019, 30(2):165-178.
[11] Lv P, Zhou M X, He J, et al. Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction[J]. International Journal of Molecular Sciences, 2014, 15(4):5774-5788.
[12] 万楠, 王璐, 郑伟, 等. 血浆miR-324-5p对单纯性先天性心脏病早期诊断的应用评估[J]. 现代检验医学杂志, 2014(5):58-59, 63.
[13] Li N, Wang K, Li P F. MicroRNA-34 family and its role in cardiovascular disease[J]. Critical Reviews in Eukaryotic Gene Expression, 2015, 25(4):293-297.
[14] 李晓伟, 奉淑君, 周凤华, 等. miR-34a在心血管疾病中的作用及机制研究进展[J]. 中国动脉硬化杂志, 2019, 27(7):624-628.
[15] Kaya B, Tayyar A, Sezer S, et al. The assessment of cardiac function with tissue Doppler imaging in fetuses with congenital diaphragmatic hernia[J]. The Journal of Maternal-fetal & Neonatal Medicine, 2020, 33(7):1233-1238.
[16] Waggoner A D, Bierig S M. Tissue Doppler imaging:A useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function[J]. Journal of the American Society of Echocardiography, 2001, 14(12):1143-1152.
[17] Yu C M, Sanderson J E, Marwick T H, et al. Tissue Doppler imaging:A new prognosticator for cardiovascular diseases[J]. Journal of the American College of Cardiology, 2007, 49(19):1903-1914.
[18] Ho C Y, Solomon S D. A clinician's guide to tissue Doppler imaging[J]. Circulation, 2006, 113(10):e396-e398.
[19] Grapsa I, Pavlopoulos H, Dawson D, et al. Retrospective study of pulmonary hypertensive patients:Is right ventricular myocardial performance index a vital prognostic factor?[J]. Hellenic Journal of Cardiology, 2007, 48(3):152-160.
[20] Dyer K L, Pauliks L B, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension[J]. Journal of the American Society of Echocardiography, 2006, 19(1):21-27.
[21] Bruch C, Schmermund A, Dagres N, et al. Tei-Index in coronary artery disease:validation in patients with overall cardiac and isolated diastolic dysfunction[J]. Zeitschrift fur Kardiologie, 2002, 91(6):472-480.
[22] Ishii M, Eto G, Tei C, et al. Quantitation of the global right ventricular function in children with normal heart and congenital heart disease:A right ventricular myocardial performance index[J]. Pediatric Cardiology, 2000, 21(5):416-421.
[23] Boucherat O, Potus F, Bonnet S. microRNA and pulmonary hypertension[J]. Advances in Experimental Medicine & Biology, 2015, 888:237-252.
[24] Wu K H, Xiao Q R, Yang Y, et al. MicroRNA-34a modulates the Notch signaling pathway in mice with congenital heart disease and its role in heart development[J]. Journal of Molecular and Cellular Cardiology, 2018, 114:300-308.
[25] Garg V, Muth A N, Ransom J F, et al. Mutations in NOTCH1 cause aortic valve disease[J]. Nature, 2005, 437(7056):270-274.
[26] Luxán G, D'Amato G, MacGrogan D, et al. Endocardial notch signaling in cardiac development and disease[J]. Circulation Research, 2016, 118(1):e1-e18.
[27] Zhou X L, Liu J C. Role of Notch signaling in the mammalian heart[J]. Brazilian Journal of Medical and Biological Research, 2014, 47(1):1-10.
[28] Guo Y M, Chao L E, Chao J L. Kallistatin attenuates endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway[J]. Journal of Cellular and Molecular Medicine, 2018, 22(9):4387-4398.
[29] Badi I, Mancinelli L, Polizzotto A, et al. miR-34a promotes vascular smooth muscle cell calcification by downregulating SIRT1(Sirtuin 1) and Axl (AXL Receptor Tyrosine Kinase)[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38(9):2079-2090.
[30] Fan F, Sun A J, Zhao H T, et al. MicroRNA-34a promotes cardiomyocyte apoptosis post myocardial infarction through down-regulating aldehyde dehydrogenase 2[J]. Current Pharmaceutical Design, 2013, 19(27):4865-4873.